Niu Xiaoting, Hu Hong, Gao Jie, Nie Yongkang, Zhao Wei, Xu Hanyi, Bai Xue, Chen Liangan
Department of Respiratory Disease, Chinese PLA General Hospital, Beijing 100853, China.
Email:
Zhonghua Jie He He Hu Xi Za Zhi. 2014 Jul;37(7):502-6.
To investigate the clinical manifestations, pathological types, treatment and prognosis of primary pulmonary lymphoma (PPL) and secondary pulmonary lymphoma (SPL).
The clinical data of 40 cases of PPL or SPL diagnosed from 2003 to 2013 in the Chinese PLA General Hospital were retrospectively analyzed. All cases were diagnosed via lung biopsy or surgical biopsy.
There were 24 male and 16 female patients, aging from 15 to 84 years, including 10 patients with PPL and 30 with SPL. The main clinical manifestations of PPL were cough and chest pain, but 4 patients were asymptomatic. Chest CT showed lung mass in 8 patients and patchy opacities in 3. ¹⁸F-FDG PET/CT showed that the SUV(max) of lung lesions was 3.96-6.70 with a median value of 4.50. The pathological types of all PPL cases were non-Hodgkin lymphoma (NHL), and 4 patients were treated with surgery combined with chemotherapy, and 3 patients were treated with surgery alone. The main clinical manifestations of SPL were cough, superficial lymph node enlargement and fever, but 8 patients were asymptomatic. The chest CT revealed pleural effusions in 20, mediastinal and hilar lymph node enlargement in 14, patch opacities in 13 and multiple nodules in 6 patients. In addition to pulmonary involvement, PET/CT examination confirmed that cervical lymph nodes, thyroid, stomach and pancreas were also involved. The SUV(max) was from 2.40 to 19.60, with a median value of 5.70. Twenty-one cases of SPL were NHL and 9 were Hodgkin lymphomas (HL). Of these patients with SPL, 14 were treated with chemotherapy alone, 8 chemotherapy combined with radiotherapy, and 2 surgery combined with chemotherapy. The one-year survival rate of PPL was 100%, compared with 93.3% of SPL. The shortest survival time of PPL was 13 months, compared with 2 months of SPL.
There were differences in the radiological features, pathological types and treatment between PPL and SPL. The chest CT manifestations of PPL were mainly lung masses, while those of SPL were mainly pleural involvement and mediastinal and hilar lymph node enlargement. The pathological type of PPL was all NHL while that of 9 cases of SPL was HL. Patients with PPL were mainly treated with surgical therapy, but SPL mainly with chemotherapy. PET/CT examination may be helpful for the diagnosis and staging of lung lymphoma. Since the misdiagnosis rate of pulmonary lymphoma was high, diagnosis must rely on lung tissue biopsy and immunohistochemistry. Compared with PPL, the prognosis of SPL is poorer.
探讨原发性肺淋巴瘤(PPL)和继发性肺淋巴瘤(SPL)的临床表现、病理类型、治疗方法及预后。
回顾性分析2003年至2013年在中国人民解放军总医院确诊的40例PPL或SPL患者的临床资料。所有病例均经肺活检或手术活检确诊。
患者中男性24例,女性16例,年龄15~84岁,其中PPL 10例,SPL 30例。PPL的主要临床表现为咳嗽和胸痛,但4例患者无症状。胸部CT显示8例患者有肺部肿块,3例有斑片状阴影。¹⁸F-FDG PET/CT显示肺部病变的SUV(max)为3.96~6.70,中位数为4.50。所有PPL病例的病理类型均为非霍奇金淋巴瘤(NHL),4例患者接受手术联合化疗,3例患者仅接受手术治疗。SPL的主要临床表现为咳嗽、浅表淋巴结肿大和发热,但8例患者无症状。胸部CT显示20例有胸腔积液,14例有纵隔和肺门淋巴结肿大,13例有斑片状阴影,6例有多发结节。除肺部受累外,PET/CT检查证实颈部淋巴结、甲状腺、胃和胰腺也有受累。SUV(max)为2.40~19.60,中位数为5.70。21例SPL为NHL,9例为霍奇金淋巴瘤(HL)。这些SPL患者中,14例仅接受化疗,8例接受化疗联合放疗,2例接受手术联合化疗。PPL的1年生存率为100%,而SPL为93.3%。PPL最短生存时间为13个月,而SPL为2个月。
PPL和SPL在影像学特征、病理类型及治疗方面存在差异。PPL的胸部CT表现主要为肺部肿块,而SPL主要为胸腔受累及纵隔和肺门淋巴结肿大。PPL的病理类型均为NHL,而9例SPL的病理类型为HL。PPL患者主要接受手术治疗,而SPL主要接受化疗。PET/CT检查可能有助于肺淋巴瘤的诊断和分期。由于肺淋巴瘤误诊率高,诊断必须依靠肺组织活检和免疫组化。与PPL相比,SPL的预后较差。